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To determine the site and mechanism of suppression
by regulatory T (Treg) cells, we investigated their
migration and function in an islet allograft model.
Treg cells first migrated from blood to the inflamed
allograft where they were essential for the suppres-
sion of alloimmunity. This process was dependent
on the chemokine receptors CCR2, CCR4, and
CCR5 and P- and E-selectin ligands. In the allograft,
Treg cells were activated and subsequently migrated
to the draining lymph nodes (dLNs) in a CCR2, CCR5,
and CCR7 fashion; this movement was essential for
optimal suppression. Treg cells inhibited dendritic
cell migration in a TGF-b and IL-10 dependent
fashion and suppressed antigen-specific T effector
cell migration, accumulation, and proliferation in
dLNs and allografts. These results showed that
sequential migration from blood to the target tissue
and to dLNs is required for Treg cells to differentiate
and execute fully their suppressive function.
INTRODUCTION
T regulatory (Treg) cells are important for maintenance of immu-
nological homeostasis and self-tolerance (Shevach, 2002). Traf-
ficking and migration to tissues and secondary lymphoid organs
are required for Treg cell function in vivo (Rudensky and Camp-
bell, 2006; Lim et al., 2006). CD103 (aEb7-integrin) has been used
to distinguish Treg subsets. Naive CD103 Treg cells express
L-selectin (CD62L) and CCR7 and recirculate through lymphoid
tissues. Effector or memory CD103+ Treg cells express high
amounts of E- and P-selectin ligands and multiple adhesion
molecules, including CD54, ICOS, b1-integrin, and LFA-1
(aLb2), as well as the inflammatory chemokine receptors CCR2,
CCR6, and CXCR3, thereby allowing efficient migration into458 Immunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc.inflamed tissues (Huehn et al., 2004). Ccr7/ Treg cells have
impaired migration into lymph nodes (LNs) and reduced
suppressive effects. In contrast, under inflammatory conditions,
effector and memory Ccr7/ Treg cells accumulate in inflamed
sites and demonstrate enhanced suppression of inflammation
(Menning et al., 2007). Thus, by regulating Treg cell trafficking
to both lymphoid and inflamed sites, CCR7 determined in vivo
function, underlining the importance of appropriate Treg cell
localization for physiologic suppression.
The question remains how important homing in lymphoid
organs versus inflamed tissues is for Treg cell-suppressive func-
tion. Our previous work shows that tolerance to cardiac allo-
grafts depended on CD62L-mediated LN homing, and genera-
tion of alloantigen-specific Treg cells occurs only in the LN but
not in the spleen or grafts (Ochando et al., 2005). In an autoim-
mune diabetes model, Treg cells control T cell priming within
the LN (Tang et al., 2006). Several studies identified Treg cells
within inflamed tissues and transplanted grafts, suggesting
these cells control effector T cells in peripheral tissues at sites
of ongoing immune responses (Belkaid et al., 2002; Lee et al.,
2005; Suffia et al., 2006). Such disparate results may be due to
differences in the numbers, activation status, and types of Treg
cells. Notably, these studies did not assess Treg cell trafficking
between tissues and dLNs; it is uncertain whether Treg primarily
exert their suppressive activity in lymphoid tissues, peripheral
tissues, or both and whether there is a relation between the
Treg subsets in the two locations.
We investigated both natural Treg (nTreg) and TGF-b-induced
Treg (TGFbTreg) cells’ migration patterns and effector function in
an islet allograft model and showed that Treg cells migrated to
and displayed suppressive effector function in both the islet
and dLN. Importantly, we demonstrated a sequential but not
a simultaneous migration pattern, such that Treg cells used P-
and E-selectin ligands and CCR2, CCR4, and CCR5 to migrate
first into the inflamed allograft. Then, Treg cells used CCR2,
CCR5, and CCR7 to migrate from the islet to the dLN. This
pattern permitted Treg cells to differentiate and display optimal
suppressive function to inhibit dendritic cell (DC) migration
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in both the islets and the dLN.
RESULTS
Treg Cells Migrate to Both Islet Allografts
and Secondary Lymphoid Tissues
To determine whether Treg cells preferentially migrate to the islet
allograft or lymphoid tissues, we isolated Treg cells, PKH26
labeled them, and intravenously adoptively transferred them to
Foxp3-GFP transgenic recipients after islet transplantation
underneath the renal capsule. Transferred PKH-labeled and
endogenous GFP-labeled T cells were monitored by fluores-
cence microscopy. Four days after islet transplantation, trans-
ferred nTreg cells, similar to endogenous nTreg cells, were
widely distributed throughout the islet allograft, the single dLN
to the kidney, the nondraining LN (ndLN), and spleen (Figures
1A and 1B; Figure S1 available online). Natural Treg cells
migrated into allografts with similar frequency to naive
CD4+CD25 T cells, which represented 0.79% of islet allograft
cells. TGFbTreg cells induced in vitro were also evaluated
because these are the Treg cells that are likely to be directly
manipulated for therapeutic interventions in humans. These
results showed that more adaptive or induced polyclonal
TGFbTreg and alloantigen-specific TGFbTEaTreg cells migrated
to islet grafts (2.1% and 2.1% of graft cells) (Figure 1B). To inves-
tigate these differences in distribution, we compared nTreg and
TGFbTreg cell phenotypes. Flow cytometric analysis showed
that both nTreg and TGFbTreg cells expressed high amounts
of CD62L (Figure 1C, right). In contrast, E-selectin (CD62E)
ligand expression was very low on naive T cells and nTreg cells,
whereas this expression was upregulated on TGFbTreg cells
(Figure 1C, left), probably as a consequence of TGF-b upregula-
tion of fucosyltransferase (Wagers and Kansas, 2000). P-selectin
(CD62P) ligand was also upregulated on TGFbTreg cells, was
low on naive T cells, and was expressed at intermediate levels
on some nTreg cells (Figure 1C, middle). The data suggest that
TGF-b-induced CD62E and CD62P ligand facilitated migration
to the allograft. It should be noted that TGFbTreg cells were stim-
ulated in vitro with CD3 mAb so that this may also influence
selectin expression or migration characteristics. Quantitative
RT-PCR for chemokine receptor expression showed that nTreg
and TGFbTreg cells expressed comparable amounts (<2-fold
difference) of chemokine receptor mRNA, with preferential tran-
scription of CCR7 and CCR6 by Treg compared to non-Treg
cells. Treg cells also expressed comparable amounts of the
sphingosine 1-phosphate receptor 1 (S1P1), which is important
for tissue and lymphatic migration (Ledgerwood et al., 2008),
but less than non-Treg cells (Figure 1D). Taken together, the
data showed that nTreg and TGFbTreg cells had similar receptor
expression, as least at the mRNA level, and migration character-
istics.
Treg Cell Migration to Islet Allografts Is Required
for Suppressive Effector Function
We next determined whether migration to islet allografts and/or
secondary lymphoid tissues was important for Treg cell effector
function.We isolatednatural Tregcells fromwild-typeandSell/,
Fut4/Fut7/, Ccr2/, Ccr4/, Ccr5/, and Ccr7/ miceto compare their migration and ability to prolong graft survival.
FucT IV-VII deficiency resulted in a lack of E- and P-selectin
ligands on leukocytes (Huang et al., 2000; Maly et al., 1996),
required for migration into inflamed tissue. CCR2, CCR4, and
CCR5 are inflammatory chemokine receptors (Sallusto et al.,
2000) required for migration into inflamed tissues. CD62L
and CCR7 are required for migration through high endothelial
venule (HEV) into LNs (Forster et al., 1999; Hemmerich et al.,
1994). Intravenously transferred nTreg cells from Fut4/Fut7/,
Ccr2/,Ccr4/, orCcr5/micemigrated normally to lymphoid
tissues but poorly to the inflamed grafts. Conversely, Sell/ and
Ccr7/ Treg cells migrated normally to grafts but poorly to LNs
(Figures 2A and 2B).
Intravenous transfer of 1 3 106 wild-type nTreg cells pro-
longed graft survival from 11.6 ± 1.1 days to 20.2 ± 1.81 days
(p < 0.05). Although there was no difference in suppressive
activity in vitro among the various gene-deficient nTreg cells
(Figure 2C), adoptive transfer of Ccr2/, Ccr4/, Ccr5/, or
Fut4/Fut7/ nTreg cells did not prolong survival (13.8 ± 1.7
days, 12.2 ± 1.6 days, 13.4 ± 1.9 days and 12.6 ± 1.4 days,
respectively, p > 0.05 versus control) (Figure 2D). In contrast,
Sell/or Ccr7/ nTreg cells prolonged survival as well as
wild-type Treg cells (24.3 ± 4.6 days, 21.5 ± 2.4 days, respec-
tively, p > 0.05 versus wild-type Treg cells). Furthermore, when
wild-type nTreg cells were transferred directly with the islets,
graft survival was even greater, suggesting that Treg cells were
required within the allograft for maximal suppressive effect and
graft protection. This was supported by the observation that
locally transferred nTreg cells from Fut4/Fut7/ and Ccr4/
prolonged survival as well as wild-type Treg cells (32.6 ±
5.9 days, 36.7 ± 2.4 days versus 35.6 ± 4.6 days, respectively,
p > 0.05) (Figure 2E). Together, these findings showed that
migration to the islet was essential to prolong graft survival,
whereas migration only from the blood to the LN via the HEV
was not required. Additional experiments demonstrated that islet
migration was required for both nTreg and TGFbTreg cells
(Figures S1 and S2).
Treg Cell Migration from Islet Graft to dLN Is Required
for Optimal Function
During these studies, we observed that locally and intravenously
transferred wild-type nTreg cells both migrated to the cortex of
the dLN, with increased numbers of Treg cells in the dLN after
local transfer compared to intravenous transfer. This indicated
that locally transferred Treg cells migrated from the graft to the
afferent lymphatics of the renal subcasular space and then into
the dLN. Thus, in addition to suppressing immunity in the
inflamed graft, another potential mechanism for increased graft
survival was the suppressive effects of Treg cells migrating to
the dLN. To explore this further, we labeled nTreg cells from
wild-type, Ccr2/, Ccr4/, Ccr5/, or Ccr7/ mice with
PKH26 and locally transferred them with islets. Ccr7/ nTreg
cells were not detected in the dLN, confirming that Treg cell entry
into afferent lymphatic vessels and migration to the dLN was
CCR7 dependent (Debes et al., 2005) (Figures 3A and 3B). There
were moderately reduced numbers of Ccr/ and Ccr5/ nTreg
in the dLN, suggesting these receptors regulated entry into
afferent lymphatics and migration to the dLN. Ccr4/ Treg cells
migrated normally from the islet to the dLN, showing that thisImmunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc. 459
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Figure 1. Treg Cell Migration to Islet Allo-
grafts and Lymphoid Tissues
(A) 1 3 106 nTreg cells labeled with PKH26 and
intravenously transferred to Foxp3-GFP islet allo-
graft recipients at the time of transplantation.
Grafts, dLNs, peripheral axillary LNs, and spleens
were harvested and sectioned 4 days later. Adop-
tively transferred Treg (red) and endogenous Treg
(green) cells are shown by fluorescent micros-
copy. Pictures representative of ten sections/
sample from three mice. Magnification is shown
at 1003.
(B) 1 3 106 nTreg, TGFbTreg, or TGFbTEaTreg
cells from Foxp3-GFPmice or CSFE-labeled naive
CD4+CD25 T cells intravenously transferred to
recipients on the day of transplantation. Four
days after transplantation, grafts, dLNs, ndLNs,
and spleen were isolated, and T cell migration
with pooled samples from two mice/group was
analyzed with flow cytometry. Results are gated
onCD3+ cells and representative of three indepen-
dent experiments. Numbers represent percentage
of cells in the gate.
(C) Comparison of CD62E ligand, CD62P ligand,
and CD62L expression on T cell subsets (gated
on CD4+Foxp3GFP+ cells). Results are represen-
tative of three independent experiments. Gating
on CD4+GFP+or CD4+GFP population is shown.
(D) qRT-PCR analysis of chemokine receptor and
S1P1 expression compared to cyclophilin expres-
sion in T cell subsets from Foxp3-GFP mice.
Freshly isolated nTreg or naive CD4+ T cells, or
cells stimulated in culture, and Treg and non-
Treg CD4+ cells separated by GFP expression
are shown. Mean + SD, n = 3 (*p < 0.05 compared
to counterpart Treg cell group).
460 Immunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc.
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Regulatory T Cell Sequential Migrationreceptor did not regulate afferent lymphatic migration. Impor-
tantly, kinetic analysis of Treg cell distribution was consistent
with migration from the graft to the dLN, and these migration
characteristics remained stable over time (Figure 3C). The kinetic
analysis also demonstrated that there was prompt lymphatic
migration from the graft to the dLN, showing that afferent
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Figure 2. Treg Cell Migration to Islet Allo-
grafts Is Important for Their Effector Func-
tion
A total of 13106wild-type,Sell/,Fut4/Fut7/,
Ccr2/, Ccr4/, Ccr5/ , or Ccr7/ nTreg cells
intravenously transferred at the time of transplanta-
tion are shown.
(A) Treg cells were labeled with PKH26, and grafts
and dLNs were harvested at day 4 and sectioned
for fluorescence microscopy. Images are repre-
sentative of 12 sections/sample from three mice/
group. Magnification is shown at 1003.
(B) PKH26-stained Treg cells were counted in the
whole graft area or dLN area in 12 consecutive
sections/sample from three mice/group (* p <
0.05 compared to wild-type control). Mean + SD,
n = 3.
(C) In vitro suppressive activity of nTreg cells from
the various mouse strains (p > 0.05 Ccr2/,
Ccr4/, Ccr5/, Ccr7/, Sell/, and Fut4/
Fut7/ versus wild-type Treg cells) was measured
by inhibition of proliferation of effector CD4+
T cells. Mean + SD, n = 3.
(D) Graft survival after intravenous transfer of 1 3
106 nTreg cells from the indicted mouse strains
(p > 0.05 for Fut4/Fut7/, Ccr2/, Ccr4/,
and Ccr5/ groups versus no Treg cell group,
p < 0.05 for wild-type, Sell/ and Ccr7/ groups
versus no Treg cell group).
(E) 1 3 106 wild-type, Ccr4/, Sell/, or Fut4/
Fut7/ nTreg cells transferred intravenously, or
mixed with islets and then transplanted under the
kidney capsule, and graft survival determined
(p < 0.05 for wild-type Treg cells local versus iv,
Fut4/Fut7/ Treg local cells versus iv groups,
and Ccr4/ local versus iv groups). (D) and (E)
compared the same no Treg, WT, and Fut4/
Fut7/ Treg iv cell groups. Results are represen-
tative of three separate preparations of islets and
Treg cells.
lymphatics were immediately functional
after the transplant procedure. The Treg
cells were unlikely to be proliferating
rapidly because there was no loss of
PKH-labeled cells in the graft or dLN
between 4–7 days. Additional controls
showed that transferred and endogenous
Treg cells expressed similar levels of che-
mokine and S1P1 receptors when
compared according to site of migration
(Figure S3).
To test the functional importance of
nTreg cell migration from allograft to
dLN, nTreg cells were transferred locally
with islets. Local transfer of wild-type
nTreg cells further prolonged islet allograft survival to 35.6 ±
4.6 days (p < 0.05 versus intravenous wild-type group). Local
transfer of Ccr4/, Fut3/Fut7/ and Sell/ nTreg cells,
which could migrate to dLN, prolonged survival as effectively
as wild-type cells (Figures 2D and 2E). However, local transfer
of Ccr2/, Ccr5/ or Ccr7/ nTreg cells did not further
Immunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc. 461
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Regulatory T Cell Sequential Migrationprolong allograft survival (Figures 2D and 3D), suggesting that
Treg cell migration from allograft to dLN was important for
suppression. To test if sequential versus simultaneous migration
of nTreg cells to the allograft and dLN were required for optimal
suppression, Ccr7/ nTreg cellswere transferred locally (and
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Figure 3. Treg Cell Migration from Islet Allo-
grafts to dLNs Is Required for Optimal Treg
Cell Function
A total of 1 3 106 wild-type, Ccr2/, Ccr4/,
Ccr5/, or Ccr7/ nTreg cells transferred with
grafts under the kidney capsule.
(A) Treg cells were labeled with PKH26, and grafts
and dLNs were harvested at day 4 and sectioned
for fluorescence microscopy. Images are repre-
sentative of 12 sections/sample from three mice/
group. Magnification is shown at 1003.
(B) PKH26-stained Treg cells counted in whole
graft area or dLN area in 12 consecutive
sections/sample from three mice/group. Mean +
SD, n = 3 (*p < 0.01, #p < 0.05 versus wild-type).
(C) nTreg cells from wild-type, Ccr2/ and
Ccr7/ Treg cells were transferred either intrave-
nously or locally to grafts; migration to grafts and
dLNs were determined 1, 4, 7, and 10 days after
transfer. Treg cells were counted in the whole graft
area or dLN area in 12 consecutive sections/
sample from three mice/group. Mean + SD, n = 3
(*p < 0.05 compared to wild-type control).
(D) Graft survival determined after local or
combined local and intravenous transfer of 1 3
106 nTreg cells from the indicated mouse strains
(p > 0.05 for Ccr2/, Ccr5/, or combined
groups versus Ccr7/ group, and p < 0.05 versus
wild-type group). Results representative of three
separate preparations of islets and Treg.
(E and F) Treg cells that migrate to the graft or to
the dLN via afferent lymphatics were measured
for the expression of CD44, CD69, and CD62L.
Wild-type, Ccr2/, or Ccr7/ nTreg cells were
labeled with PKH26, transferred as indicated into
islet allograft recipients, isolated 4 days after trans-
plantation, and analyzed by (E) fluorescent flow
cytometry and (F) qRT-PCR (pooled samples
from four mice/group and gated on CD4+PKH26+
population, mean + SD, n = 2, *p < 0.05 versus
nTreg before transfer).
thus were excluded from the dLN) and
Ccr2/ nTreg cells were transferred
intravenously (and thus were excluded
from the grafts) to the same recipients,
so that nTreg cells would migrate simulta-
neously but not sequentially to both
allograft and dLN. Graft survival was not
prolonged beyond Ccr7/ or Ccr2/
transfer alone, and was not as great as
local transfer of wild-type nTreg cells
alone (Figure 3D), demonstrating that
sequential nTreg cell migration from the
allograft to the dLN was required for
optimal suppression.
We next investigated why nTreg cells that migrated from blood
to graft and then into the dLN were functionally different from
nTreg cells that entered the dLN directly. Wild-type, Ccr7/
and Ccr2/ nTreg were transferred intravenously or locally, so
that nTreg cells that migrated from the allograft via afferent
462 Immunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc.
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distinguished. These separate nTreg cells were compared by
flow cytometry and RT-PCR for relevant markers. The results
(Figures 3E and 3F) showed that wild-type or Ccr7/ nTreg
became activated in the allograft, with increased expression of
CD44 and CD69 and decreased expression of CD62L. Wild-
type nTreg cells that migrated by afferent lymphatics to the
dLN had the same activation pattern. In contrast, wild-type
nTreg cells that migrated to ndLNs or Ccr2/ nTreg cells that
migrated to dLNs by HEV were not activated. Activated nTreg
cells upregulated the expression of the effector molecules
IL-10, TGF-b, and granzyme B, but not perforin or granzyme A.
Thus, the sequential migration of nTreg cells from blood to tissue
to dLN resulted in differentiation to an activated effector pheno-
type, correlating with more effective suppression and prolonga-
tion of graft survival.
Treg Cells Inhibit T Cell Accumulation in the Islet
and dLN
To explore why Treg cells were required in two sites and how the
differentiation and activation of Treg cells manifested as optimal
suppression, we performed histochemical analysis. Islet allo-
grafts showed less leukocyte infiltration after transfer of
TGFbTEaTreg cells compared to controls, and local transfer
preserved islet structure better than intravenous transfer
(Figure 4A). Consistent with the morphological findings, flow
cytometric analysis showed that 12.6%of islet cells (40,000 cells)
were CD4+ in the control group, 5.2% (16,000 CD4+ T cells) were
so in the TGFbTEaTreg cell intravenous transfer group, and
3.3% (11,000 CD4+ T cells) were so in the TGFbTEaTreg cell
local transfer group (Figures 1B and 5B; Figures S1 and S4). As
expected, there was a greater percentage of Treg cells in the
islets of the local transfer group (4.6% or 15,000 cells) compared
to the intravenous transfer group (1.1% or 3300 cells).
Draining LNs also showed decreased hypertrophy and accu-
mulation of recipient CD4+ T cells after transfer of TGFbTEaTreg
cells (Figures 1B and 4B; Figures S1 and S4). Thus, recipient
CD4+ T cells in the dLN were 36% of the total LN cells
(89,000cells) in controls, 29% (57,000 cells) in the intravenous
Treg cell transfer group, and 27% (43,000 cells) in the local
Treg cell transfer group (Figure 4B). Treg cells did not change
CD4+ T cell content at distal sites, such as the ndLN or spleen
(Figure 1B). Together, these results showed that Treg cells
inhibited inflammation at both sites and that suppressing inflam-
mation at the graft inhibited downstream dLN hypertrophy, prob-
ably by suppressing cytokine and chemokine production in the
graft (Chen et al., 2006).
To explore the effect of Treg cells on antigen-specific T cells in
the islets and dLNs, we cotransferred wild-type nTreg cells
labeled with PKH26 with alloantigen-specific, naive, TEa
CD4+CD25 T cells labeled with CSFE. Intravenously transferred
nTreg cells reduced accumulation of TEa T cells in both allografts
(from 1.2% or 6500 islet cells to 0.8% or 3600 islet cells) and
dLNs (from 1.4% or 7400 dLN cells to 0.7% or 4300 dLN cells)
(Figure 4C; Figure S5). Local transfer of wild-type nTreg cells
further reduced the accumulation of TEa CD4+ T cells in both
allografts (1600 cells or 0.3% of islet cells) and dLNs (800 cells
or 0.1% of dLN cells) (Figure 4C; Figure S5). Transferred nTreg
cells also reduced the proliferation of TEa CD4+ T cells in bothallografts and dLNs (Figure 4D). Together, these data showed
that Treg cells inhibited accumulation of specific effector
T cells in islets and the dLN, probably through effects on migra-
tion, proliferation, and/or survival.
To explore immunosuppressive effects at specific sites, we
transferred receptor deficient nTreg cells. Local transfer of
Ccr7/ nTreg cells resulted in large numbers of Treg cells
retained within the graft, but none detected in the dLN (Figures
3A and 4C; Figure S5). Even though Ccr7/ nTreg cells were
retained in the graft, they were far less effective than wild-type
Treg cells in inhibiting TEa CD4+ T cell migration into both islets
and dLNs (Figure 4C; Figure S5) or at prolonging survival
(Figure 3D), although the Ccr7/ nTreg cells were intrinsically
suppressive (Figures 2D and 3D). This shows that large numbers
of nTreg cells within the graft were not sufficient for optimal
immunosuppression and survival and that in particular, their
presence did not fully inhibit effector T cell migration into the
graft. Intravenously transferred Ccr2/ nTreg cells, which
migrated to dLNs but not to islets (Figure 2B; Figure S5), were
also less effective than wild-type nTreg cells in inhibiting effector
T cell migration into islets (Figure 4C; Figure S5). Thus, Treg cells
located only in grafts or only in dLNs were not sufficient for full
suppressive effects for prolonging survival or for inhibiting
effector T cell migration into grafts or dLNs. Together with the
results showing activation and upregulated effector molecules
(Figures 3E and 3F), these findings demonstrate that Treg cells
must not only be in both sites but also havemigrated sequentially
from tissue to dLNs to become activated for full suppressive
function.
Treg Cells Inhibit DC Migration
To explore the possibility that Treg cells also inhibited DC func-
tion, we used CX3CR1-GFP mice, in which islet DCs are inter-
nally labeled with GFP (Jung et al., 2000), as islet donors. After
PKH26-labeled TGFbTreg cells were intravenously transferred,
Treg cell-DC juxtaposition could be visualized in the graft
(Figure 5A, panels on left), with decreased numbers of DC found
in dLNs (Figure 5A), suggesting direct interactions of Treg cells
and DCs inhibited DC migration from the graft to the dLN. An
in vitro model was developed to further explore this interaction.
Freshly isolated islets from CX3CR1-GFP mice were cultured
for 24 hr, and migration of the GFP+ DC out of the islets in
response to CCL21 was monitored. Thirty-five percent to fifty
percent of islet DCsmigrated in response toCCL21, and addition
of Treg cells to the culture inhibited this response (Figures 5B and
5C). If a permeable membrane separated the islets and Treg
cells, DC migration was still inhibited (Figure 5C). As shown
above, Treg cells produce TGF-b and IL-10. Blocking TGF-b
and/or IL-10with specificmAbs restored DCmigration, and add-
ing recombinant purified TGF-b or IL-10, without Treg cells,
inhibited DCmigration (Figures 5D and 5E). Together, these find-
ings demonstrated that Treg cells inhibited islet DC migration by
secreting TGF-b and IL-10. To show the significance of IL-10 for
Treg cell function in vivo, we locally transferred nTreg cells from
wild-type or Il10/ mice to grafts. Local transfer of wild-type
nTreg cells prolonged graft survival; however, Il10/ nTreg cells
were significantly impaired in their ability to prolong survival
(Figure 5F). To further show the important role of Treg cell-
derived IL-10, we transplanted BALB/c CX3CR1-GFP islets toImmunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc. 463
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Regulatory T Cell Sequential MigrationFigure 4. TGFbTEaTreg Preserve Islet Structure
and Inhibit Effector T Cell Infiltration of Islet Allo-
grafts
(A and B) 1 3 106 TGFbTEaTreg cells transferred intrave-
nously or locally to grafts.
(A) Treg cells preserve islet structure. Grafts were har-
vested 7 days after transplantation and processed for
H&E staining. Pictures representative of ten sections/graft
from three mice/group. Magnification is shown at 1003.
(B) Treg cells migrate to islets and dLNs and prevent CD4+
T cell infiltration. Allografts and dLNs harvested 7 days
after transplantation dispersed into single-cell suspen-
sions and stained with anti-CD4 mAb for flow cytometry.
(C and D) 1 3 106 CSFE-labeled naive TEa CD4+ T cells
intravenously injected and 1 3 106 PKH26-labeled nTreg
cells transferred intravenously or locally into recipients at
the time of transplantation.
(C) Treg cells migrate to islets and dLNs and prevent
antigen-specific T cell infiltration. Grafts, dLNs, ndLNs,
and spleens were harvested 4 days after transplantation
and analyzed with flow cytometry. Cell percentages and
numbers are shown.
(D) Treg cells prevent effector T cell proliferation. Prolifer-
ation of CSFE-labeled TEa CD4+ T cells was analyzed by
CSFE dilution; percent undivided cells are shown.
Samples from two mice/group per experiment pooled for
analysis are shown. Results are representative of three
independent experiments in (B)–(D).464 Immunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc.
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A Figure 5. Treg Cells Inhibit the Migration of
Islet DCs by Secreting TGFb and IL-10
(A) Treg cells inhibit DC migration from the graft to
the dLN. PKH26-labeled TGFbTreg cells were
intravenously transferred along with CX3CR1-
GFP BALB/c islets to C57BL/6 recipient mice.
Transferred TGFbaTreg cells and DC were
enumerated 1 and 4 days later by microscopy
and cell counting. Treg, red; DC, green. Pictures
are representative of 12 sections/graft from two
mice. Magnification is shown at 1003 in the left
panel and at 4503 in the middle and right panels.
GFP + DCs in islet grafts or dLNs were counted
in the whole graft or dLN areas in 12 consecutive
sections/sample from three mice/group. Mean +
SD, n = 3 (* p < 0.05 compared to CD4+ control
group).
(B) DCs migrate out of islets in vitro. Islets from
CX3CR1-GFP mice were cultured with or without
CCL21 (0.5 mg/ml) for 24 hr and GFP+ DCs were
visualized by fluorescent (upper panel) and light
microscopy (lower panel). Pictures are representa-
tive of observations in nine independent experi-
ments. Magnification is shown at 503.
(C) Treg cells inhibit DC migration out of islets.
CX3CR1-GFP islets were incubated with the indi-
cated chemokine and T cells. Mean + SD, n = 3
(* p < 0.05 versus CCL21 group).
(D) IL-10 and TGF-b inhibit DC migration out of
islets. CX3CR1-GFP islets were incubated with
the indicated chemokine and cytokines. Mean +
SD, n = 3 (* p < 0.05 versus CCL21 group).
(E) IL-10 and TGF-b antibodies block the inhibitory
effect of Treg cells on DC migration out of islets.
CX3CR1-GFP islets were incubated with the
indicated chemokine, Treg cells, and mAbs.
Mean + SD, n = 3 (* p < 0.05 versus CCL21 group).
Calculations are based on 100 islets/group per
experiment, and results are representative of three
independent experiments in (C)–(E).
(F) Treg cell-derived IL-10 is required to prolong
graft survival. Graft survival after local transfer of
1 3 106 wild-type or Il10/ nTreg cells with islets
is shown. Results are representative of three sepa-
rate preparations of islets and Treg cells.
(G) Treg cell-derived IL-10 is required to inhibit DC
and T effector cell migration. C57BL/6 mice
received BALB/c CX3CR1-GFP islets, local trans-
fer of wild-type or Il10/ nTreg cells, and intrave-
nous transfer of PKH26-labeled naive TEa CD4+
T cells. Islet DC and TEa CD4+ T cell migration
were analyzed by flow cytometry after 4 days.
Samples from two mice/group per experiment
were pooled for flow cytometry analysis. Results
are representative of three independent experi-
ments.
(H) DC migration initiates early graft rejection.
Swap70/ 129/Sv EMS or 129/Sv EMS islets
transplanted to BALB/c recipients. Results are
representative of two separate preparations of
islets and Treg cells.Immunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc. 465
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transferred locally, and PKH26-labeled TEaCD4+CD25 effector
T cells transferred intravenously. Flow cytometric analysis of
grafts and dLNs showed that wild-type nTreg cells inhibited
graft-derived DC migration to dLN, along with inhibiting TEa
effector T cell infiltration into both graft and dLNs. Il10/ nTreg
cells failed to inhibit islet derived DC migration to the dLN and
were less inhibitory for TEa effector T cell migration to both the
graft and the dLN (Figure 5G; Figure S6). Together, these data
showed that Treg cell secretion of IL-10 in the graft inhibited
both donor DC egress from and recipient T cell entry into the
islets. To determine the significance of donor-derived DCmigra-
tion to dLNs for graft survival, we transplanted Swap70/ islets.
SWAP-70 is involved in actin rearrangement and cell migration
(Shinohara et al., 2002; Sivalenka and Jessberger, 2004), and
SWAP-70 deficiency results in a profound reduction in DCmigra-
tion to dLNs (Ochando et al., 2006). Swap70/ grafts survived
longer than wild-type islets (23.6 ± 3.5 days versus 10.6 ±
1.6 days, p < 0.05), suggesting that impaired donor-derived
DC migration to dLNs favored graft survival (Figure 5H).
DISCUSSION
Here, we showed that natural Treg and TGFbTreg cells express
a panel of trafficking molecules and chemokine receptors orient-
ing their migration to both the inflammatory bed of grafts and
dLNs to prolong islet allograft survival. Treg cell migration to
grafts was essential for their in vivo suppressive function. Treg
cells’ protective effects for graft survival were abrogated if they
failed to migrate to the graft because of CCR2, CCR4, CCR5,
or P- and E-selectin ligand deficiency, and protection was
enhanced when Treg cells were delivered locally into the grafts.
TGF-b-induced Treg cells upregulated E-selectin ligand expres-
sion, as well as more efficiently migrated to and protected grafts.
Strikingly, Treg cell migration from the graft to the dLN was also
required for optimal suppression, and dLN migration depended
on CCR2, CCR5, and CCR7. The recent demonstration (Huehn
et al., 2004; Kocks et al., 2007) that CCR7 and LN migration
are necessary for Treg cell function are consonant with our find-
ings. In addition, our data showed the important finding that
CCR7 was required for afferent lymphatic rather HEV transmi-
gration of Treg cells into the dLN, in order to prolong graft
survival. Some important limitations to our interpretations relate
to the model employed here. Adoptive transfer of Treg cells
results in greater numbers than could be mobilized from endog-
enous sources, and therefore the results may not be entirely
reflective of endogenous Treg cell physiology, although our
comparisons of transferred and endogenous Treg cells demon-
strated congruent receptor expression and migration character-
istics. Transplantation to the renal subcapsular space exposes
a unique set of blood microvascular and lymphatic vessels, so
that the choice of chemokines and receptorsmay vary according
to the intrinsic tissue characteristics. Lastly, measurements of
chemokine receptors relied on mRNA rather than functional
protein, although RT-PCR results were commensurate with the
gene-deficiency migration studies in vivo.
Our data demonstrated that nTreg cells that sequentially
migrated from the blood to the islets and then to the dLN
acquired an activated phenotype, whereas those that entered466 Immunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc.the dLN via HEV did not. This suggests a functionally important
differentiation and activation step that accompanies the migra-
tion of Treg cells. This also suggests that nTreg cells may be effi-
ciently primed or activated at the site of tissue inflammation. In
contrast, conventional effector T cells are expected to be primed
and activated in the dLN. Similarly, our previous results in
a cardiac allograft model suggested that adaptive or peripherally
induced TGFbTreg cells are also primed and activated in dLNs
(Ochando et al., 2005). In the present study, Treg cells directly
suppressed effector T cell migration, proliferation, and accumu-
lation in both the dLN and in the graft; Treg cells had tomigrate to
the dLN to optimally suppress effector T cell infiltration of the
graft; and inhibition of both dLN and graft infiltration were depen-
dent on Treg cell production of IL-10. Treg cells targeted donor-
derived islet DCs, inhibiting their migration by secreting TGF-b
and IL-10. Together, these results suggested that migration to
the site of inflammation and then to dLNs was both necessary
for Treg cells to differentiate and execute fully their suppressor
function, so that Treg cells interact with DCs in the peripheral
tissue and then target effector T cells in the dLN.
Similar to our findings, in a colitis model Treg cells cotrans-
ferred with pathogenic T cells migrate to mesenteric LNs and
the inflamed colon and are located between clusters of CD11c+
cells and pathogenic T cells (Mottet et al., 2003); however, the
relationship of the Treg cells at the two sites to each other was
not defined. Evidence from autoimmune and transplantation
models suggests that CD62Lhi and CCR7+ Treg cells with
lymphoid tissue tropism are superior to CD62Llo or CCR7 Treg
cells in preventing autoimmunity or suppressing graft-versus-
host disease (Ermann et al., 2005; Szanya et al., 2002; Taylor
et al., 2004). Tanget al. (2006) demonstrated that antigen-specific
Treg cells inhibit effector T cell and DC priming interactions in the
cortex of the LN in the NODmodel of autoimmune diabetes. Our
study in a cardiac allograft model showed that alloantigen-
specific Foxp3+ Treg cells accumulate in the LNs of tolerant
animals, and inhibition of T cell LN migration prevents tolerance
(Ochandoet al., 2005). Alterative conclusions hinted at the impor-
tance of other trafficking events in the function of Treg.Chen et al.
(2005) showed that islet autoantigen-specific Treg cells prevent
diabetes by inhibiting effector T cell function in the islet. In the
cardiac transplantation model, Lee et al. (2005) reported CCR4-
dependent recruitment of Treg cells to the allograft. The islet
transplantmodel here provided the opportunity to examine spec-
ificity, site of action, and changes in the transplanted tissue and
dLN arising from the migration and suppressive activity of Treg
cells. Our findings reconcile these other reports by showing that
nTreg cells migrated first to the grafts and then migrated from
the graft to the dLN. Importantly, these two activities were func-
tionally tightly linked, given that preventing Treg cell migration
to grafts but not to LNs (as in intravenous transfer of Fut4/
Fut7/, Ccr2/, Ccr4/, or Ccr5/ Treg cells) or restraining
Treg cells solely to the graft (as in intravenous transfer ofCcr7/
Treg cells, or local transfer of Ccr2/, Ccr5/, or Ccr7/ Treg
cells) all limited the suppressive capabilities of Treg cells to
prolong survival. Treg cell migration to the graft alone afforded
significant survival advantage, whereas migration to the dLN via
theHEValoneprovided noprotection. Importantly, the cotransfer
ofCcr7/ Treg cells locally andCcr2/ Treg cells intravenously,
in which the Treg cells were constrained to the graft and LN,
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anddLNswas not as effective as sequentialmigration to promote
suppression. Rather, it was necessary that Treg cells first enter
the graft and then migrate to the dLN in order to differentiate
and acquire the activated phenotype.
Studies on effector T cell development demonstrated that Treg
cells prevent clonal expansion and differentiation by limiting
access to DCs (Fiorina et al., 2007; Tadokoro et al., 2006; Tang
et al., 2006). The results here demonstrated that Treg cells limited
effector T cell migration, proliferation, and accumulation within
the dLN. This effect was probably multifactorial because of the
suppressive effects of Treg cells on islet chemokine expression,
islet donor-derived DCmigration, and direct effects of Treg cells
ondLNDCantigenpresentation and effector T cell responses. An
important finding was that locally transferred Treg cells optimally
inhibited effector T cell infiltration of grafts only when the Treg
cells migrated to the dLN. The presence of Treg cells in the graft
alone, such as with Ccr7/ Treg cells, was not sufficient to
prevent effector T cell migration into the graft. This indicated
that Treg cell migration from the graft to the dLNwas of functional
significance for suppressive effects in the graft. These results
suggested that effector T cells are primed in the dLN, exit through
efferent lymphatics, and enter the inflammatory islet bed via the
microvasular circulation and that Treg cells inhibit effector T cell
priming or exit from the dLN (Sarween et al., 2004).
Our findings resolve diverse data from various studies
addressing the location of Treg cells for suppression in vivo.
Treg cells have dynamic trafficking properties, homing first to
the islet allograft from blood in a selectin- and chemokine-
dependent fashion and then migrating from the graft to the
dLN in a chemokine- and perhaps S1P1-dependent fashion,
acquiring an activated phenotype along the way. Critical targets
of Treg cells included DCs, effector T cells, and islet paren-
chymal cells producing chemokines. The findings suggest that
nTreg cells may be initially stimulated at sites of tissue inflamma-
tion, whereas adaptive TGFbTreg cells may be initially stimulated
in lymphoid tissues. Manipulation of Treg cell differentiation and
dynamic trafficking may be therapeutically beneficial for immu-
notherapy designed to engage their suppressive function.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6 (wild-type, Ccr2/, Ccr5/, Sell/, and Il10/) and BALB/c mice
(8–10 weeks) were purchased from The Jackson Laboratory (Bar Harbor, ME,
USA). CX3CR1-GFP (Jung et al., 2000) mice on BALB/c backgrounds were
from D. Littman (New York University). Foxp3GFP (Fontenot et al., 2005) and
TEa TCR transgenic (Grubin et al., 1997) mice on a C57BL/6 background
were from A. Rudensky (University of Washington). The TEa TCR transgene
recognizes I-Ed peptide presented bu I-Ab.Ccr7/ (Forster et al., 1999), fuco-
syltransferase Fut4/Fut7/ (Maly et al., 1996) (J. Lowe, Cleveland Clinic)
and Ccr4/ (Schuh et al., 2002) mice (C. Hogaboam, University of Michigan)
were all on a C57BL/6 background. Swap70/ 129/Sv EMS and congenic
129/Sv EMS mice have been described (Ochando et al., 2006; Shinohara
et al., 2002). All experiments were performed with age- and sex-matched
mice in accordance with Institutional Animal Care and Utilization
Committee-approved protocols.
Reagents
Collagenase P was from Roche Diagnostics (Mannheim, Germany). PE-CD33
(clone 145-2C11), PerCP-Cy5.5-CD4 (clone RM4-5), FITC-CD25 (clone 7D4),PE-Foxp3 (clone 3G3), APC-CD11c (clone HL3), PE-Cy7-CD62L (clone
MEL-14), anti-IL-10 (JES5-2A5), and anti-TGFb (clone 1D11) were from BD
PharMingen (San Diego, CA, USA). A chimeric E-selectin Ig (Huang et al.,
2000) was from J. Lowe. A chimeric P-selectin Ig was from P.S. Frenette
(Mount Sinai). CFSE was from Molecular Probes (Eugene, OR, USA). PKH26
dye was from Sigma-Aldrich (St. Louis, MO, USA). Recombinant murine
CCL21 was from R&D Systems (Minneapolis, MN, USA).
Islet Isolation and Transplantation
BALB/c (H-2d) islets were isolated as previously reported (Zhang et al., 2004).
Pancreata were perfused with collagenase P, harvested, digested, and puri-
fied over a discontinuous Ficoll gradient. A total of 400 freshly isolated islets
were transplanted to streptozocin-induced diabetic (blood glucose
>300 mg/dl) C57BL/6 (H-2b) recipients. Blood glucose <150 mg/dl after trans-
plantation was considered engraftment, and >300mg/dl was considered islet-
graft rejection.
Islet-Graft Single-Cell Preparations
Recipient mice were sacrificed, islet grafts were exposed by partially peeling
the capsule from the kidney surface, harvested, and digestedwith collagenase
P (1.5 mg/ml) at 37C water bath for 5 min, and gently made into a single-cell
suspension through a nylon mesh.
Cell Staining and Flow Cytometric Analysis
Staining was performed with the specific antibody (1 mg/106 cells) at 4C for
30 min. Cells were analyzed with the FACSCaliber flow cytometer with CELL-
QuestTM software (BD Biosciences, Mountain View, CA, USA). Data were
analyzed with FlowJo software (Tree Star, Ashland, OR, USA). To compare
Treg cells in islet grafts, LNs or spleen, we stained all single-cell suspension
and gated it on CD3+ cells for further analysis.
Cell Purification and Primary Cell Culture
nTreg and TGFbTreg cells were stimulated and purified, and in vitro suppres-
sive function was assayed with MLR as previously described (Fu et al., 2004).
To sort nTreg or naive CD4+ T cells, we harvested spleens from the indicated
strains of mice and removed red blood cells using hypotonic lysis buffer. Sple-
nocytes were enriched for CD4+ T cells with CD4+ negative selection kit (R&D
Systems). Cells were stained with APC anti-mouse CD4, FITC anti-mouse
CD25, and PE anti-mouseCD8 for 30min on ice. CD4+CD25+ andCD4+CD25
cells were sorted with FACS Vantage DiVA (BD Bioscience) or MoFlo (DakoCy-
tomation, Fort Collins, CO, USA). Flow cytometry confirmed that the purity of
sorted cells was greater than 99%, and greater than 98% of sorted
CD4+CD25+ cells were CD4+Foxp3+. In experiments with TGFbTreg or
TGFbTEaTreg cells, Foxp3GFP transgenic and TEa/Foxp3GFP double-trans-
genic mouse were used. CD4+Foxp3GFP+ T cells and CD4+Foxp3GFP
T cells were sorted with the above procedure, but gated on Foxp3GFP rather
than FITC anti-mouse CD25. T cell-depleted splenocytes were used as stim-
ulator antigen-presenting cells (APCs). For stimulating cultures to generate
activated T cells or TGFbTreg cells, purified CD4+Foxp3GFP wild-type or
TEa transgenic cells (5 3 104 cells/well) were cultured with gamma-irradiated
(800 Rad) syngeneic APCs (53104 cells/well) in the presence of IL-2 (10 ng/ml)
and CD33 mAb (1 mg/ml), with or without TGF-b (5 ng/ml) in a final volume of
200 ml of complete RPMI medium (RPMI-1640 supplemented with 10% fetal
bovine serum, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 IU/ml penicillin,
100 mg/ml streptomycin, and nonessential amino acids) in U-bottomed 96-well
plates (Corning, Lowell, MA, USA) for 5 days. Cultured cells were then stained
with CD4 and resorted for CD4+Foxp3GFP+ and CD4+Foxp3GFP cells.
T Cell Suppression Assay
Subsets of Treg cells and CD4+ T cells were sorted as described above and
used in a suppression assay. Freshly sorted responder CD4+CD25 T cells
(5 3 104 cells/well) were cultured in the absence or presence of Treg ce;;s
(responder: suppressor ratio of 1:1 and 8:1) with irradiated (800 Rad) synge-
neic T cell-depleted splenocytes (5 3 104 cells/well) and CD33 mAb (1 mg/ml)
for 3 days. Cells were pulsed with 1 mCi[3H]TdR for the last 18 hr of culture. The
incorporated [3H]TdR was measured with a Wallac Betaplate Counter (Perki-
nElmer, Boston, MA, USA).Immunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc. 467
Immunity
Regulatory T Cell Sequential MigrationTreg Cell Adoptive Transfers
Treg or control cell suspensions were differentially labeled with PKH26 or
CFSE, and 1 3 106 labeled Treg cells in 300 ml of PBS were injected intrave-
nously; alternatively, 1 3 106 Treg cells were mixed and pelleted with freshly
isolated islets and then transplanted in 20 ml of PBS. At the indicated times
after adoptive transfer, islet grafts, draining LNs, spleen, and peripheral axillary
LNs were harvested and single-cell suspensions or tissue sections were
prepared.
Quantitative Real-Time PCR
RNA isolation, reverse transcription to cDNA, PCR conditions, and chemokine
receptor and S1P1 primer sequences were previously published (Ledgerwood
et al., 2008), with additional primer sequences for IL-10 forward 50-
AGTGCCTGGTTGCTGCTTTACC-30 and reverse 50-AGCCGTAGGGTCTTTA
GATTTTC AC-30; TGF-b forward 50-CTGCTGAGGCTCAAGTTAAAAGTG-30
and reverse 50-CAGCCGGTTGCTGAGGTAG-30; perforin forward 50-GAGAA
GACCTATCAGGACCA-30 and reverse 50-AGCCTGTGGTAAGCATG-30;
granzyme A forward 50-TTTCATCCTGTAATTGGACTAA-30 and reverse
50-GCGATCTCCACACTTCTC-30; granzyme B forward 50-CCTCCTGCTA
CTGCTGAC-30 and reverse 50-GTCAGCACAAAGTCCTCTC-30. mRNA
expression levels were quantified by real-time PCR with SYBR Green PCR
kit (QIAGEN, Valencia, CA, USA) with the LightCycler 2.0 (Roche Diagnostic
Corp, Indianapolis, IN, USA). PCR consisted of a 15 min 95C denaturation
step followed by 45 cycles of 15 s at 94C, 20 s at 56C, and 20 s at 72C.
Normalized values for specific gene mRNA expression were calculated as
follows: 2(Ct of Cyclophilin A – Ct-specific gene). We calculated relative fold expression
by dividing the specific gene mRNA expression with mRNA expression in
control T cells. Each RNA sample was run in duplicate, and each experimental
group consisted of two to three individual samples so that values for statistical
analysis could be generated.
In Vitro Islet DC Migration Assays
CX3CR1-GFP islets were incubated in complete RPMI-1640 medium contain-
ing 10% FBS (Sigma-Aldrich) in 24-well plates and exposed to CCL21
(0.5 mg/ml) for 24 hr. The numbers of CX3CR1-GFP cells that migrated out of
islets (mDCs) and thatwere retained inside the islets (rDCs) were counted under
the fluorescence microscope. Percent migration was calculated as mDC/
(mDC + rDC)3 100%.
Immunofluorescent Microscopy
Fresh islet grafts, LNs, and spleens were harvested, frozen directly in Optimal
Cutting Temperature (OCT) (Sacura Finetek, CA, USA), and stored at 80C.
Sections of 5 mm were cut with a Leica 1900CM cryomicrotome, and slides
were mounted with Vectashield mounting solution (Vector Laboratories, Bur-
lingame, CA, USA), with or without DAPI. Images were acquired with a Leica
DMRA2 fluorescence microscope and a digital Hamamatsu close circuit
device camera. Separate images were collected on the CY3, GFP, and DAPI
channels, overlaid, and analyzed with Openlab software (Improvision, Lexing-
ton, MA, USA).
In Vitro Transwell Migration Assays
In vitro migration assays were performed as previously described (Ledger-
wood et al., 2008). A total of 3 3 105 CSFE-labeled CD4+CD25 T cells in
RPMI 1640 containing 0.5% fatty acid-free BSA (Sigma-Aldrich) mixed with
PKH26-labeled Treg cells at different ratios were added in a volume of 100 ml
to the upper wells of a 24-well transwell plate with a 5mm insert (Corning Inter-
national, Corning, NY, USA). Lower wells contained various concentrations of
CCL19 in 600 ml of RPMI 1640/0.5% fatty acid-free BSA. The number of T cells
that migrated to the lower well after 4 hr incubation was counted under a fluo-
rescent microscope with a hemocytometer.
Statistics
In vivo migration results represent pooled samples from two to three mice per
group per experiment. In vitro migration results represent mean values of trip-
licate samples. All experiments were performed two to five times. Data are pre-
sented as mean ± standard deviation. Comparisons between groups were
done by independent sample t tests or analysis of variance (ANOVA) between
groupswithMicrosoft Excel software. Differences between graft survival times468 Immunity 30, 458–469, March 20, 2009 ª2009 Elsevier Inc.were assessed by Kaplan-Meier survival analysis with StatView software. p <
0.05 was considered statistically significant.
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